Prime

Type your tag names separated by a space and hit enter

[Therapy with vasopressin receptor antagonists: the aquaretics.].

Abstract

Aquaretic drugs, by definition, can induce an increase in urinary volume and urinary free water associated with a decreased urinary osmolarity with a consequent increase in plasma sodium. This enhanced diuresis is not accompanied by an increased loss of electrolytes, whereas traditional diuretics have the opposite, so-called saluretic effect. Aquaretics belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate tubular water reabsorption. Several studies have confirmed their utility in the treatment of hyponatremic states associated with water retention such as heart failure, cirrhosis related ascites and SIADH. Furthermore, new applications may include the treatment of arterial hypertension, polycystic kidney disease, glaucoma and Meniere's syndrome.

Authors

, , , , , , ,

Source

Pub Type(s)

English Abstract
Journal Article

Language

ita

PubMed ID

17886207

Citation

TY - JOUR T1 - [Therapy with vasopressin receptor antagonists: the aquaretics.]. AU - Buemi,M, AU - Bolignano,D, AU - Coppolino,G, AU - Sturiale,A, AU - Campo,S, AU - Crasci',E, AU - Aloisi,C, AU - Frisina,N, PY - 2007/9/22/pubmed PY - 2007/9/22/medline PY - 2007/9/22/entrez SP - 371 EP - 80 JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia JO - G Ital Nefrol VL - 24 IS - 5 N2 - Aquaretic drugs, by definition, can induce an increase in urinary volume and urinary free water associated with a decreased urinary osmolarity with a consequent increase in plasma sodium. This enhanced diuresis is not accompanied by an increased loss of electrolytes, whereas traditional diuretics have the opposite, so-called saluretic effect. Aquaretics belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate tubular water reabsorption. Several studies have confirmed their utility in the treatment of hyponatremic states associated with water retention such as heart failure, cirrhosis related ascites and SIADH. Furthermore, new applications may include the treatment of arterial hypertension, polycystic kidney disease, glaucoma and Meniere's syndrome. SN - 0393-5590 UR - https://www.unboundmedicine.com/medline/citation/17886207/full_citation/[Therapy_with_vasopressin_receptor_antagonists:_the_aquaretics_] L2 - http://journals.indexcopernicus.com/ICinfoauthor.php?PMID=17886207 ER -